ABT-751 With Chemotherapy for Relapsed Pediatric ALL

Exclusion Criteria

• •5. During the phase II portion of the trial, patients must have no more than 3 prior therapeutic attempts and it must be at least 6 months since the last treatment with a "VPLD" induction/re-induction regimen.
• •5. Reproductive Function
• •1. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment and within 48 hours of starting therapy.
• •2. Female patients with infants must agree not to breastfeed their infants while on this study.
• •3. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for 3 months following completion of therapy.
• •1. Drug Allergies
• •Patients will be excluded if they have allergies to the following drugs:
• •* Asparaginase products
• •* Sulfa containing medications
• •2. Renal Function Patients will be excluded if their serum creatinine is \> the upper limit of normal (ULN) for age at the institution's laboratory.
• •3. Liver/Pancreatic Function
• •1. Direct bilirubin \> 1.5x the institutional ULN for age. A total bilirubin result that is less than 1.5 times the institutional ULN for age may be used for eligibility if a direct bilirubin result is not available.
• •2. SGPT (ALT) \> 4 x institutional ULN
• •3. Grade 3 or greater pancreatitis as defined by the CTCAE v3.0
• •4. Amylase or Lipase \> 2 x institutional ULN
• •4. Cardiac Function Patients will be excluded if their shortening fraction by echocardiogram is less than 30%.
• •5. Infection Patients will be excluded if they have an active, uncontrolled infection.
• •1. Patients with grade 2 or greater motor or sensory neuropathy per CTC 3.0 criteria.
• •2. Patients with grade 2 or greater Ileus (neuroconstipation) per CTC 3.0 criteria.
• •3. Patients currently being treated with coumadin.
• •4. Patients currently being treated with colchicines.
• •5. Patients planning on receiving other investigational agents while on this study. (An investigational agent is defined as any drug not currently approved for use in humans.)
• •6. Patients planning on receiving other anti-cancer therapies while on this study.
• •7. Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
• •8. Patients who, based on BSA and current dose level, require a daily dose of ABT-751 that is less than 25mg per day.
• •9. Patients who have started protocol therapy prior to enrollment. Patient may still enroll if IT Ara-C or IT MTX were given within 48 hours of study enrollment as part of the diagnostic lumbar procedure. These patients will not participate in the CSF PK portion of the study.